Kathy D Miller
Big Ten Cancer Research Consortium · Hoosier Cancer Research Network · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kathy D Miller as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:18 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02575339 · MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular CarcinomaKathy Miller · terminated · Hepatocellular Carcinoma, Liver Cancer, HCC · principal investigator
- Ph2NCT01074970 · PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsHoosier Cancer Research Network · completed · Breast Cancer · study chair
- Ph3NCT00433511 · Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast CancerNational Cancer Institute (NCI) · active not recruiting · Breast Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT00433511
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT00433511
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:18 UTC. The ranking covers the 200 most relevant of 64 PubMed records, and a shared surname and initials can bring in a namesake. All 64 on PubMed
- Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.J Clin Oncol · 20051,039 citationsRCR 22.6
- 536 citationsRCR 11.8
- 415 citationsRCR 9.3
- A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.Semin Oncol · 2003371 citationsRCR 7.0
- 339 citationsRCR 17.2
- 338 citationsRCR 8.7
- 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.Clin Cancer Res · 2017306 citationsRCR 11.4
- 298 citationsRCR 7.3
- 267 citationsRCR 11.0
- Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial.J Clin Oncol · 2000265 citationsRCR 7.9